Indeed, there are emerging reports suggesting that synergy can be achieved with the combination of CDK4/6 inhibitors and PI3K inhibitors in breast cancer [49] or with insulin-like growth factor receptor 1 (IGF1R) inhibitors in pancreatic cancer [50]. This evidence concerns the gene IGF1R and familial pancreatic carcinoma.